Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 30,869

Document Document Title
WO/2023/211930A1
The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, infl...  
WO/2023/211812A1
The present invention is related to compounds of structure (I) as mitogen-activated protein kinase (MEK) and/or ERK inhibitors. (Formula (I)). The variables are described herein.  
WO/2023/207556A1
The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound represented by formula (A) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate ...  
WO/2023/205914A1
The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.  
WO/2023/201423A1
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...  
WO/2023/201421A1
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...  
WO/2023/205269A1
The present invention relates to electrochromic devices and compositions, which include a cathodic component that includes cathodic zwitterions, where an anion is covalently bonded by a divalent linking group to a pyridinium nitrogen of ...  
WO/2023/205173A1
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...  
WO/2023/202623A1
Provided in the present invention are a POLQ inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and use thereof in preparing a drug for preventing or...  
WO/2023/205336A1
The present invention relates to electrochromic devices and compositions, in which the cathodic component has cationic charge and includes counter-anions, where each counter-anion of the cathodic component is an anodic component having a...  
WO/2023/202582A1
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...  
WO/2023/205465A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...  
WO/2023/205219A1
Provided herein are E2 binding PROTACS and uses thereof.  
WO/2023/202502A1
The present invention relates to an azole-containing organic compound and use thereof. The azole-containing organic compound has a structure represented by structural formula I, , Ar1-Ar3 is one of substituted or unsubstituted C6-C30 ary...  
WO/2023/205310A1
The present invention relates to electrochromic devices and compositions, in which the anodic component thereof includes an anodic component anion selected from at least one anodic component anion represented by the following Formulas (I...  
WO/2023/202336A1
Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and/or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of dr...  
WO/2023/202545A1
Provided in the present invention is the use of a diphenyl pyrazole compound represented by general formula (I) or a pesticidally acceptable salt thereof as a herbicide synergist. The compound is an inhibitor targeting GSTs in farmland w...  
WO/2023/204642A1
Provided are: a compound of chemical formula 1, having inhibitory activity against protein kinase, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and use thereof.  
WO/2023/204668A1
The present invention provides a novel compound and an organic light emitting device comprising same.  
WO/2023/198180A1
The present invention relates to a novel compound of general formula (A) capable of inhibiting and inducing degradation of EGFR, and a pharmaceutical composition comprising the compound, which can be used for treating diseases associated...  
WO/2023/198172A1
Disclosed are an oxadiazole compound having a structure of formula (I), a pharmaceutical composition comprising same, and the use thereof as an HDAC6 inhibitor.  
WO/2023/200195A1
The present invention relates to an organic compound, which is employed for an organic layer, such as a hole transport layer or an electron block layer, of an organic light emitting diode. The organic compound according to the present in...  
WO/2023/198873A1
The application relates to isoxazolyl-pyrazole derivatives of the general formula (I) for the treatment of diseases and conditions such as psoriasis, autoimmune thyroiditis, inflammatory bowel disease and cancer in which inverse agonism ...  
WO/2023/200315A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2023/200964A1
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...  
WO/2023/198140A1
The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.  
WO/2023/199091A1
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.  
WO/2023/196985A1
Disclosed herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A and A' are each independently selected from the group consisting of: (a1), (a2), (a3), (4) and (a5) and B, B', X and Y have the meani...  
WO/2023/194339A1
The present invention relates to a crystalline form of lanifibranor having an X-ray diffraction pattern in accordance with figure 1.  
WO/2023/194622A1
The invention relates to a use of combinations of PD-1 inhibitor therapy with certain kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants,...  
WO/2023/194895A1
This invention relates to novel compounds which are inhibitors of APOL1, pharmaceutical compositions containing the compounds, processes for their preparation, and uses thereof in therapy for the treatment of kidney diseases and sepsis.  
WO/2023/195529A1
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...  
WO/2023/196283A1
The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.  
WO/2023/194162A1
The present invention relates to a compound of general formula (I) and also the stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salts thereof, and also to the use thereof for the prevention and/or tr...  
WO/2023/185931A1
The present invention relates to a P2X3 inhibitor compound, a salt thereof, a polymorph thereof and use thereof. The present invention provides a crystalline form of a compound of formula I, which has good medicinal properties. A pharmac...  
WO/2023/186102A1
The present invention provides a Nav1.8 inhibitor. Particularly, the present invention provides a compound represented by formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug the...  
WO/2023/187391A1
The present invention relates to compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (Ia) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic ...  
WO/2023/185831A1
The present application relates to a compound containing a thiazole ring, and specifically to a compound of formula I, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof in treating diseases such...  
WO/2023/185864A1
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that bin...  
WO/2023/191379A1
The present disclosure relates to a 3,4-dihydroquinoxaline-2-carboximide derivative compound and a pharmaceutical composition comprising same for preventing or treating a cancer disease. The compound has an excellent effect of selectivel...  
WO/2023/192388A1
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (...  
WO/2023/186069A1
A bifunctional chimeric heterocyclic compound of interleukin-1 receptor-associated kinase 4 (IRAK4) represented by formula (I), a preparation method therefor, a pharmaceutical composition thereof and use thereof. The compound recruits IR...  
WO/2023/192801A1
The present disclosure provides certain sulfonamido derivatives that are Cyciin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical composit...  
WO/2023/180189A1
Disclosed are novel viral Mpro inhibitors according to Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to inhibit Mpro and...  
WO/2023/182780A1
The present invention relates to a novel thiazole derivative compound, a compound selected from pharmaceutically acceptable salts thereof, solvates thereof or stereoisomers thereof, and a medical use thereof. The present invention provid...  
WO/2023/183850A1
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors. Additional utilities and advantages are described herein.  
WO/2023/178928A1
Disclosed in the present invention are 2-amino-4-indolyl pyrimidine compounds, a preparation method therefor, and the uses thereof, belonging to the technical field of drug synthesis. Specifically, the present invention relates to pyrimi...  
WO/2023/178378A1
The present disclosure generally relates to pipecolic acid derived compounds, in particular pipecolic acid derived compounds of Formula (I), and to formulations and compositions comprising the same. The present disclosure also relates to...  
WO/2023/183377A1
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I (I) Also disclosed are methods o...  
WO/2023/182775A1
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.  

Matches 251 - 300 out of 30,869